xTAG® CYP2C19 Kit v3 is a genotyping panel covering clinically relevant mutations and offering the ability to identify CYP2C19*2 and CYP2C19*3 variants, which together account for approximately 99% of Asian and 87% of Caucasians poor metabolizers, respectively. Over one-third of Caucasians and over 40% of patients of African and Asian ancestry harbor gain-of-function and loss-of-function 2C19 variants.1 These variants are linked to a higher risk of adverse events with certain drugs. The test incorporates multiplex Polymerase Chain Reaction (PCR) and multiplex Allele Specific Primer Extension (ASPE) on the Luminex platforms. The assay automatically determines the diplotype for each sample.
Features of the xTAG CYP2C19 Kit v3:
Genotypes (EU-IVD/SFDA Approved) — *2, *3, *4, *5, *6, *7, *8, *9, *10, *17
Instrument & Software — Luminex 100/200 instrument with xPONENT® 3.1 software and MAGPIX instrument with xPONENT 4.2 software.
Reproducibility — 100%
Kit Accuracy — 100% compared to Dideoxy Sequencing (after allowable reruns)
Optimal Input DNA — 0.5 ng/μL to 300 ng/μL (US)
Sample Type — EDTA Blood & Citrate Blood
xTAG CYP2C19 Kit v3 Workflow
Scalable: Flexible throughput with the Luminex system
Ease of use: All-inclusive kit containing necessary reagents and enzymes
Efficient: Multiple IVD assays on the same platform and optimized workflow for each assay saves time
The xTAG® CYP2C19 Kit v3 is a qualitative genotyping assay which can be used as an aid to clinicians in determining therapeutic strategy for the therapeutics that are metabolized by the CYP2C19 gene product, specifically *1, *2, *3, *4, *5, *6, *7, *8, *9, *10 and *17.